(A) Application of SLIGKV-NH2 (100 μM, 4 min) increased the sEPSC frequency as documented in recording from one superficial dorsal horn neuron. (B) The amplitude of the sEPSCs did not change during SLIGKV-NH2 application (100 μM, 4 min, n = 17). (C) Application of SLIGKV-NH2 (100 μM, 4 min) increased the sEPSC frequency compared to the pre-treatment values set as 100% (n = 17; ***p < 0.001). Application of TRPV1 antagonist SB 366791 (10 μM, 4 min, n = 10) or staurosporine (250 nM, 4 min, n = 9) prevented the excitatory effect of SLIGKV-NH2 treatment and the mean sEPSC frequency values were statistically different from the application of SLIGKV-NH2 alone (#p < 0.05).